A dose-ranging study of imeglimin in Japanese type 2 diabetic subjects

Trial Profile

A dose-ranging study of imeglimin in Japanese type 2 diabetic subjects

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Jul 2017

At a glance

  • Drugs Imeglimin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Poxel
  • Most Recent Events

    • 30 Jun 2017 Status changed from active, no longer recruiting to completed.
    • 06 Jun 2017 Results published in a Poxel media release.
    • 06 Jun 2017 Data will be presented at the European Association for the Study for Diabetes 53rd Annual Meeting 2017, according to a Poxel media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top